SciLifeLab
Browse

File(s) not publicly available

Reason: These data constitute sensitive personal information that falls under The General Data Protection Regulation of the European Union (GDPR).

Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19

dataset
posted on 2024-07-22, 09:06 authored by August JernbomAugust Jernbom, Lovisa Skoglund, Elisa PinElisa Pin, Ronald Sjöberg, Hanna Tegel, Sophia Hober, Elham Rostami, Annica Rasmusson, Janet L. Cunningham, Sebastian Havervall, Charlotte ThålinCharlotte Thålin, Anna MånbergAnna Månberg, Peter Nilsson

Note: The DOI of the related paper will be provided upon publication.

These datasets contain information on autoantibody and anti-SARS-CoV-2 IgG levels.

In this study, 478 healthcare workers and 48 patients were followed prospectively over 5 visits from May 2020 to Sept 2021. SARS-CoV-2 serology and autoantibodies were assessed using planar and bead-based arrays. Detected epitopes were validated in blood and cerebrospinal fluid from two independent cohorts of Neuro-COVID patients (n=25) and pre-pandemic healthy controls (n=29).

The datasets contain:

  • SARS-CoV-2 serological profiles measured in all samples (above) using 3-plex bead arrays. The data is reported as raw and normalized MFI (AU) and compound serostatus.
  • Proteome-wide autoantibody profiles measured in 12 sample pools using planar arrays. The data is reported as median fluorescent intensity, in raw and normalized arbitrary units (MFI [AU]), and reactivity classification.
  • Targeted autoantibody profiles measured in 478 healthcare workers and 48 patients across 5 time points using 363-plex bead arrays. The data is reported as raw and normalized MFI (AU), fold change (FC) across infection, and new-onset classification.
  • Peptide epitope mapping autoantibody profiles measured in a 142 healthcare workers and COVID-19 patients across 2 time points, and all Neuro-COVID patients (n=25) and pre-pandemic healthy controls (n=29), using 93-plex bead arrays. The data is reported as raw and normalized MFI (AU), and fold change (FC) across infection.

Source data is provided with the paper.

Access to this individual-level human data can be granted for non-commercial validation purposes and upon reasonable request to the provided contact. A reasonable request should contain the following:

  1. Name of PI and host organization
  2. Contact details
  3. The scientific purpose of the data access request
  4. Commitment to inform when the data has been used in a publication
  5. Commitment not to host or share the data outside the requesting organization
  6. Statement of non-commercial use of data

Funding

The post-COVID associated autoantibody repertoire

Swedish Research Council

Find out more...

History

Publisher

KTH Royal Institute of Technology

Access request email

peter.nilsson@scilifelab.se

SciLifeLab acknowledgement

  • Autoimmunity and Serology Profiling unit

Usage metrics

    Science for Life Laboratory

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC